Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Joseph P. Lyssikatos Sells 12,000 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $17.92, for a total value of $215,040.00. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Joseph P. Lyssikatos also recently made the following trade(s):

• On Thursday, April 11th, Joseph P. Lyssikatos sold 30,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.04, for a total value of $751,200.00.
• On Monday, April 1st, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $18.60, for a total transaction of $223,200.00.
• On Thursday, February 29th, Joseph P. Lyssikatos sold 12,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.42, for a total transaction of $197,040.00.

Enliven Therapeutics Stock Up 4.1 %

Shares of Enliven Therapeutics stock opened at $18.10 on Thursday. Enliven Therapeutics, Inc. has a 1-year low of $9.80 and a 1-year high of $26.00. The business’s fifty day moving average price is $17.20 and its two-hundred day moving average price is $14.59.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, analysts predict that Enliven Therapeutics, Inc. will post -2.16 EPS for the current fiscal year.

Institutional Trading of Enliven Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after acquiring an additional 3,189 shares in the last quarter. AJOVista LLC acquired a new stake in Enliven Therapeutics in the fourth quarter worth approximately $28,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Enliven Therapeutics by 17.8% during the 4th quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock valued at $187,000 after purchasing an additional 2,041 shares during the period. Finally, Exchange Traded Concepts LLC increased its position in shares of Enliven Therapeutics by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock valued at $121,000 after purchasing an additional 2,208 shares during the period. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target on the stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.